-
2 days ago | 
insideprecisionmedicine.com | Chris Anderson
Researchers at the Keck School of Medicine of USC have found a compound that disrupts the internal clockwork of glioblastoma stem cells, showing safety in humans and promising results in a Phase I clinical trial. Results from the trial, published in Neuro-Oncology, focused on SHP1705, a compound that activates specifically CRY2, a chryptochrome protein, to suppress the transcriptional activity of BMAL1 and CLOCK, key components of the circadian clock machinery.
-
3 days ago | 
insideprecisionmedicine.com | Chris Anderson
Researchers at the Palacký University in Czechia have discovered blood-based biomarkers that can predict failure of treatment in patients with both metastatic hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC) prostate cancer.
-
4 days ago | 
insideprecisionmedicine.com | Chris Anderson
A team of scientists in Australia has discovered a small molecule that selectively blocks a key protein involved in cell death, a finding that could lead to the development of treatments for neurodegenerative conditions such as Parkinson’s disease and Alzheimer’s disease (AD).
-
1 week ago | 
insideprecisionmedicine.com | Chris Anderson
A vitamin-based therapy aimed at improving retinal metabolism may offer a new neuroprotective strategy for patients with glaucoma, according to new research published in Cell Reports Medicine. The study, led by scientists at Sweden’s Karolinska Institutet, found that supplements of vitamins B6, B9, B12, and choline slowed or halted damage to the optic nerve in animal models of glaucoma, even without reducing intraocular pressure (IOP), which is the goal of current glaucoma treatments.
-
1 week ago | 
insideprecisionmedicine.com | Chris Anderson
HIV medications known as nucleoside reverse transcriptase inhibitors (NRTIs) may significantly reduce the risk of Alzheimer’s disease (AD), according to new research led by scientists at UVA Health. Analyzing millions of health records, the researchers found that patients who took NRTIs had markedly lower rates of AD compared to those who didn’t take the drugs.
-
1 week ago | 
insideprecisionmedicine.com | Chris Anderson
A new study by researchers at Mass General Brigham has identified a treatment sequence that improves survival for patients with relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL), a rare and aggressive blood cancer with no established treatment protocol. R/R TNKLs are notoriously difficult to treat due to their biological heterogeneity, resistance to standard therapies, and lack of clearly effective treatment options.
-
1 week ago | 
insideprecisionmedicine.com | Chris Anderson
Researchers at the Massachusetts Institute of Technology (MIT) have developed a new molecular tool that allows them to selectively label and visualize a complex sugar molecule unique to Mycobacterium tuberculosis (Mtb), the pathogen responsible for tuberculosis (TB). Their findings, published in the Proceedings of the National Academy of Sciences (PNAS), could lead to faster, simpler, urine-based diagnostic methods for TB that work even when traditional tests fail.
-
1 week ago | 
insideprecisionmedicine.com | Chris Anderson
A research team led by Lucía Chávez-Gutiérrez, PhD, at the VIB-KU Leuven Center for Brain & Disease Research has developed a method to predict the onset of familial Alzheimer’s disease (AD) by analyzing genetic mutations in key proteins involved in amyloid-beta (Aβ) processing.
-
2 weeks ago | 
insideprecisionmedicine.com | Chris Anderson
A single mutation in a key DNA methylation enzyme has been shown to disrupt tumor-suppressing pathways and increase the risk of developing blood cancer, according to researchers at Australia’s Olivia Newton-John Cancer Research Institute (ONJCRI) and the Walter and Eliza Hall Institute of Medical Research (WEHI).
-
2 weeks ago | 
insideprecisionmedicine.com | Chris Anderson
Researchers from the Université Laval in Québec have shown in a recent study that a noninvasive eye exam analyzing the retina could diagnose early signs of Parkinson’s disease (PD) years in advance before motor symptoms appear. The research, published in Neurobiology of Disease, details how the retina in people with PD responds differently to light than it does in healthy people, suggesting it could be used as an early biomarker of PD development.
